iCo Therapeutics Receives “Outperform” Rating from Zacks (ICOTF)
iCo Therapeutics (NASDAQ:ICOTF)‘s stock had its “outperform” rating restated by Zacks in a research note issued on Friday. They currently have a $0.90 target price on the stock. Zacks‘s price target suggests a potential upside of 190.79% from the company’s current price.
Zacks’ analyst wrote, ” On May 29, 2014, iCo Therapeutics Inc. reported financial results for the first quarter 2014. The company had net income of CAD$1.365 million, or $0.02 per share, which was attributable to a significant increase in the value of the investment in Immune Pharmaceuticals. Top-line results from the Phase 2 iDEAL study should be available in June 2014. The company raised CAD$6.75 million in the first quarter, which will fully fund the iDEAL study and see the company through the release of the full results in the September/October time frame. “
Shares of iCo Therapeutics (NASDAQ:ICOTF) traded up 14.21% during mid-day trading on Friday, hitting $0.3095. The stock had a trading volume of 144,960 shares. iCo Therapeutics has a 52-week low of $0.227 and a 52-week high of $0.533. The stock has a 50-day moving average of $0.30 and a 200-day moving average of $0.37. The company’s market cap is $26.1 million.
iCo Therapeutics (NASDAQ:ICOTF) last issued its quarterly earnings data on Friday, May 30th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.01.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.